Stock Info

Company Overview

Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre’s pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23.

Latest News
Jun 18, 2024

Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks compared to dosing every two weeks...

Jun 3, 2024

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and...

May 29, 2024

Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and...

View All News

Corporate Presentation

07/08/2024

Spyre Corporate Overview

View All Presentations

Latest Events
Wednesday, June 5, 2024
9:30am - 10:30am EDT

View All Events

Investor Contact
Investor Email Alerts
* Required Fields